Иматиниб мезилат и комбинированная химиотерапия в лечении пациентов с недавно диагностированным острым лимфобластным лейкозом с положительной филадельфийской хромосомой
Международное исследование фазы 3 при остром лимфобластном лейкозе (Ph+ALL) в Филадельфии с положительной хромосомой. Тестирование иматиниба в комбинации с двумя различными цитотоксическими химиотерапевтическими основами
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
- Другой: Laboratory Biomarker Analysis
- Лекарство: Cyclophosphamide
- Лекарство: Doxorubicin
- Лекарство: Vincristine Sulfate
- Другой: Questionnaire Administration
- Лекарство: Daunorubicin Hydrochloride
- Лекарство: Etoposide
- Лекарство: Mercaptopurine
- Лекарство: Methylprednisolone
- Лекарство: Ifosfamide
- Лекарство: Calaspargase Pegol
- Лекарство: Leucovorin Calcium
- Лекарство: Methotrexate
- Лекарство: Cytarabine
- Лекарство: Dexamethasone
- Лекарство: Dexrazoxane Hydrochloride
- Биологический: Filgrastim
- Лекарство: Imatinib Mesylate
- Лекарство: Levoleucovorin
- Лекарство: Pegaspargase
- Лекарство: Prednisolone
- Лекарство: Therapeutic Hydrocortisone
- Лекарство: Thioguanine
- Процедура: Allogeneic Hematopoietic Stem Cell Transplantation
Подробное описание
PRIMARY OBJECTIVE:
I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.
SECONDARY OBJECTIVES:
I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.
III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.
IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.
V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.
VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.
EXPLORATORY OBJECTIVES:
I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.
II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.
III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.
IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.
IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.
IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.
V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.
VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.
VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).
VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.
VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.
IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.
X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.
XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.
XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.
OUTLINE:
INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.
INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.
INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.
POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.
ARM A (SR patients assigned to ARM A):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM B (SR PATIENTS ASSIGNED TO ARM B):
INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.
DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.
INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.
MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.
ARM C (HR PATIENTS):
CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.
CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.
HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.
POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed up every year for 3 years.
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, Австралия, 2310
- John Hunter Children's Hospital
-
Randwick, New South Wales, Австралия, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Австралия, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Австралия, 4101
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Австралия, 6008
- Princess Margaret Hospital for Children
-
Perth, Western Australia, Австралия, 6009
- Perth Children's Hospital
-
-
-
-
-
Vienna, Австрия, 1090
- St. Anna Children's Hospital
-
-
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Бельгия, 3000
- Hospitals Leuven
-
-
-
-
-
Hamburg, Германия, 20246
- Universitätsklinik Eppendorf
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Германия, 24105
- University Medical Center chleswig- Campus Kiel
-
-
-
-
Kowloon
-
Kowloon Bay, Kowloon, Гонконг
- Hong Kong Children's Hospital
-
-
-
-
Central District
-
Petah Tikva, Central District, Израиль, 4920235
- Schneider Children's Medical Center of Israel
-
-
-
-
-
Monza, Италия, 20900
- Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM
-
-
-
-
-
Québec, Канада, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Канада, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Канада, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Канада, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Канада, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Канада, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Канада, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Канада, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Канада, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Канада, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Канада, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Канада, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Канада, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Канада, S7N 4H4
- Saskatoon Cancer Centre
-
Saskatoon, Saskatchewan, Канада, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Utrecht, Нидерланды, 3584 CT
- Princess Máxima Center for Pediatric Oncology
-
-
-
-
-
Christchurch, Новая Зеландия, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Новая Зеландия, 1145
- Starship Children's Hospital
-
-
-
-
-
Caguas, Пуэрто-Рико, 00726
- HIMA San Pablo Oncologic Hospital
-
San Juan, Пуэрто-Рико, 00926
- University Pediatric Hospital
-
San Juan, Пуэрто-Рико, 00912
- San Jorge Children's Hospital
-
-
-
-
-
Riyadh, Саудовская Аравия, 11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Соединенные Штаты, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Соединенные Штаты, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Соединенные Штаты, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Соединенные Штаты, 85719
- Banner University Medical Center - Tucson
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Соединенные Штаты, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Соединенные Штаты, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Соединенные Штаты, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Соединенные Штаты, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Соединенные Штаты, 90027
- Children's Hospital Los Angeles
-
Madera, California, Соединенные Штаты, 93636
- Valley Children's Hospital
-
Oakland, California, Соединенные Штаты, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Соединенные Штаты, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Соединенные Штаты, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Соединенные Штаты, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Соединенные Штаты, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Соединенные Штаты, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Соединенные Штаты, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Children's Hospital Colorado
-
Denver, Colorado, Соединенные Штаты, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Соединенные Штаты, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Соединенные Штаты, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Соединенные Штаты, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Lauderdale, Florida, Соединенные Штаты, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Соединенные Штаты, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Соединенные Штаты, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Соединенные Штаты, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Соединенные Штаты, 32207
- Nemours Children's Clinic-Jacksonville
-
Loxahatchee Groves, Florida, Соединенные Штаты, 33470
- Palms West Radiation Therapy
-
Miami, Florida, Соединенные Штаты, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Соединенные Штаты, 33176
- Miami Cancer Institute
-
Orlando, Florida, Соединенные Штаты, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Соединенные Штаты, 32803
- AdventHealth Orlando
-
Orlando, Florida, Соединенные Штаты, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Соединенные Штаты, 32504
- Sacred Heart Hospital
-
St. Petersburg, Florida, Соединенные Штаты, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Соединенные Штаты, 33606
- Tampa General Hospital
-
Tampa, Florida, Соединенные Штаты, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Соединенные Штаты, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Соединенные Штаты, 30912
- Augusta University Medical Center
-
Macon, Georgia, Соединенные Штаты, 31201
- Atrium Health Navicent
-
Savannah, Georgia, Соединенные Штаты, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Соединенные Штаты, 60612
- University of Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Lurie Children's Hospital-Chicago
-
Oak Lawn, Illinois, Соединенные Штаты, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Соединенные Штаты, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Соединенные Штаты, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Соединенные Штаты, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Соединенные Штаты, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Соединенные Штаты, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Соединенные Штаты, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Соединенные Штаты, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Соединенные Штаты, 21215
- Sinai Hospital of Baltimore
-
Bethesda, Maryland, Соединенные Штаты, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, Соединенные Штаты, 02111
- Tufts Children's Hospital
-
Worcester, Massachusetts, Соединенные Штаты, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Соединенные Штаты, 48201
- Children's Hospital of Michigan
-
Detroit, Michigan, Соединенные Штаты, 48236
- Henry Ford Health Saint John Hospital
-
East Lansing, Michigan, Соединенные Штаты, 48823
- Michigan State University
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Соединенные Штаты, 49007
- Bronson Methodist Hospital
-
Royal Oak, Michigan, Соединенные Штаты, 48073
- Corewell Health Children's
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Соединенные Штаты, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Соединенные Штаты, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Соединенные Штаты, 65212
- University of Missouri Children's Hospital
-
Kansas City, Missouri, Соединенные Штаты, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Соединенные Штаты, 63141
- Mercy Hospital Saint Louis
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Соединенные Штаты, 68114
- Children's Hospital and Medical Center of Omaha
-
-
Nevada
-
Las Vegas, Nevada, Соединенные Штаты, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Соединенные Штаты, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Соединенные Штаты, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Соединенные Штаты, 89102
- University Medical Center of Southern Nevada
-
Reno, Nevada, Соединенные Штаты, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Соединенные Штаты, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Соединенные Штаты, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Соединенные Штаты, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Соединенные Штаты, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Соединенные Штаты, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Соединенные Штаты, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Соединенные Штаты, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Соединенные Штаты, 07503
- Saint Joseph's Regional Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87106
- Presbyterian Hospital
-
Albuquerque, New Mexico, Соединенные Штаты, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Соединенные Штаты, 12208
- Albany Medical Center
-
Brooklyn, New York, Соединенные Штаты, 11219
- Maimonides Medical Center
-
Buffalo, New York, Соединенные Штаты, 14263
- Roswell Park Cancer Institute
-
Mineola, New York, Соединенные Штаты, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Соединенные Штаты, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Соединенные Штаты, 10029
- Mount Sinai Hospital
-
New York, New York, Соединенные Штаты, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Соединенные Штаты, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Соединенные Штаты, 14642
- University of Rochester
-
Stony Brook, New York, Соединенные Штаты, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Соединенные Штаты, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Соединенные Штаты, 10467
- Montefiore Medical Center - Moses Campus
-
Valhalla, New York, Соединенные Штаты, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Соединенные Штаты, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Соединенные Штаты, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Соединенные Штаты, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Соединенные Штаты, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke University Medical Center
-
Greenville, North Carolina, Соединенные Штаты, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Соединенные Штаты, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Соединенные Штаты, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Соединенные Штаты, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Соединенные Штаты, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Соединенные Штаты, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Соединенные Штаты, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health and Science University
-
Portland, Oregon, Соединенные Штаты, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Соединенные Штаты, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Соединенные Штаты, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Соединенные Штаты, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Соединенные Штаты, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Соединенные Штаты, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Соединенные Штаты, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Соединенные Штаты, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Соединенные Штаты, 37403
- T C Thompson Children's Hospital
-
Knoxville, Tennessee, Соединенные Штаты, 37916
- East Tennessee Childrens Hospital
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Соединенные Штаты, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Amarillo, Texas, Соединенные Штаты, 79106
- Texas Tech University Health Sciences Center-Amarillo
-
Austin, Texas, Соединенные Штаты, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Соединенные Штаты, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Соединенные Штаты, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Соединенные Штаты, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Соединенные Штаты, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Соединенные Штаты, 76104
- Cook Children's Medical Center
-
Houston, Texas, Соединенные Штаты, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Соединенные Штаты, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Соединенные Штаты, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Соединенные Штаты, 79415
- UMC Cancer Center / UMC Health System
-
San Antonio, Texas, Соединенные Штаты, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Соединенные Штаты, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Соединенные Штаты, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84113
- Primary Children's Hospital
-
-
Vermont
-
Burlington, Vermont, Соединенные Штаты, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- University of Virginia Cancer Center
-
Falls Church, Virginia, Соединенные Штаты, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Соединенные Штаты, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Соединенные Штаты, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Соединенные Штаты, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Соединенные Штаты, 24014
- Carilion Children's
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Соединенные Штаты, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Соединенные Штаты, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Соединенные Штаты, 98431
- Madigan Army Medical Center
-
-
West Virginia
-
Huntington, West Virginia, Соединенные Штаты, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Соединенные Штаты, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Соединенные Штаты, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Соединенные Штаты, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marshfield, Wisconsin, Соединенные Штаты, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Tampere, Финляндия, 33521
- Tampere University Hospital
-
-
-
-
-
Rennes, Франция, 35203
- CHU Hopital Sud
-
-
-
-
-
Prague, Чехия, 15018, 5-Motol
- University Hospital Motol
-
-
-
-
-
Santiago, Чили
- Hospital Roberto del Rio-Universidad de Chile
-
-
-
-
-
Zurich, Швейцария, CH8032
- University Children's Hospital
-
-
-
-
Skåne County
-
Lund, Skåne County, Швеция, 22185
- Skane University Hospital
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled
- For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
- In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
-
>= 1 year (365 days) and =< 21 years at ALL diagnosis
-
Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies
-
ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)
-
Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy
-
Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine
-
Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib
-
ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)
-
ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2
-
Direct bilirubin =< 2.0 mg/dL
-
Shortening fraction of >= 27% by echocardiogram
-
Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram
-
Corrected QT interval, QTc < 480 msec
- Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:
- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)
Exclusion Criteria:
-
Known history of chronic myelogenous leukemia (CML)
-
ALL developing after a previous cancer treated with cytotoxic chemotherapy
-
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
-
Down syndrome
-
Pregnancy and breast feeding
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
-
Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block
-
Prior treatment with dasatinib, or any TKI other than imatinib
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: Arm A (imatinib mesylate, EsPhALL chemotherapy)
See Detailed Description |
Correlative studies Given IV
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Ancillary studies Given IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Given PO or IV
Другие имена:
Given IT
Другие имена:
Given IV, SC, or IT
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given SC or IV
Другие имена:
Given PO
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given IT
Другие имена:
Given PO
Другие имена:
|
|
Экспериментальный: Arm B (imatinib mesylate, COG/BFM chemotherapy)
See Detailed Description. |
Correlative studies Given IV
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Ancillary studies Given PO
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Given PO or IV
Другие имена:
Given IT
Другие имена:
Given IV, SC, or IT
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given PO
Другие имена:
|
|
Экспериментальный: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)
See Detailed Description |
Correlative studies Given IV
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Ancillary studies Given IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Given IV
Другие имена:
Given PO or IV
Другие имена:
Given IT
Другие имена:
Given IV, SC, or IT
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given SC or IV
Другие имена:
Given PO
Другие имена:
Given PO or IV
Другие имена:
Given IV
Другие имена:
Given PO
Другие имена:
Given IT
Другие имена:
Given PO
Другие имена:
Undergo HSCT
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Временное ограничение: Up to 3 years
|
Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone. |
Up to 3 years
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Временное ограничение: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Временное ограничение: Up to 2 years
|
The proportion of patients who receive at least 75% of intended doses. |
Up to 2 years
|
|
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Временное ограничение: Up to 3 years
|
Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events. |
Up to 3 years
|
|
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Временное ограничение: Up to 3 years
|
Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group. |
Up to 3 years
|
|
EFS of all Ph+ patients
Временное ограничение: Up to 3 years
|
Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first. |
Up to 3 years
|
|
Overall survival (OS) of all Ph+ patients
Временное ограничение: Up to 3 years
|
Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause. |
Up to 3 years
|
|
OS of SR Ph+ patients
Временное ограничение: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients |
Up to 3 years
|
|
OS of SR Ph+ patients by randomization group
Временное ограничение: Up to 3 years
|
Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
OS of high risk Ph+ patients
Временное ограничение: Up to 3 years
|
Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients. |
Up to 3 years
|
|
EFS of all eligibility ABL-class fusion positive ALL patients
Временное ограничение: Up to 3 years
|
Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
|
OS of all eligibility ABL-class fusion positive ALL patients
Временное ограничение: Up to 3 years
|
Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients. |
Up to 3 years
|
Другие показатели результатов
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Временное ограничение: Up to 2 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection. |
Up to 2 years
|
|
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Временное ограничение: Up to 3 years
|
Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm. |
Up to 3 years
|
|
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Временное ограничение: Up to 6 months
|
For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB. |
Up to 6 months
|
|
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Временное ограничение: Up to 3 years
|
The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored. |
Up to 3 years
|
|
MRD assessments made by IGH-TCR PCR assay and NGS assay
Временное ограничение: Up to 3 years
|
Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected. |
Up to 3 years
|
|
IKZF1 deletions alone
Временное ограничение: Up to 3 years
|
Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
IKZF1 deletions with other transcription factor deletions
Временное ограничение: Up to 3 years
|
Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Other identified genetic lesions
Временное ограничение: Up to 3 years
|
Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631. |
Up to 3 years
|
|
Frequency of p190 and p210 BCR::ABL1 fusion variants
Временное ограничение: Up to 3 years
|
For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL. |
Up to 3 years
|
|
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Временное ограничение: Up to 2 years
|
Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity. |
Up to 2 years
|
|
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Временное ограничение: Up to 2 years
|
Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity. |
Up to 2 years
|
|
DFS of SR ABL-class fusion positive patients
Временное ограничение: Up to 3 years
|
Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone. |
Up to 3 years
|
|
Secondary and exploratory aims applied to ABL-class fusion positive patients
Временное ограничение: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
Therapeutic impact of major secondary events
Временное ограничение: Up to 3 years
|
Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events. |
Up to 3 years
|
|
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Временное ограничение: Up to 3 years
|
Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients. |
Up to 3 years
|
|
In vivo activity
Временное ограничение: Up to 3 years
|
Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631. |
Up to 3 years
|
|
Molecular heterogeneity
Временное ограничение: Up to 3 years
|
Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
Cellular heterogeneity
Временное ограничение: Up to 3 years
|
Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays. |
Up to 3 years
|
|
CML-like phenotypes
Временное ограничение: Up to 3 years
|
Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions. |
Up to 3 years
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Следователи
Следователи
- Главный следователь: Lewis B Silverman, Children's Oncology Group
- Главный следователь: Andrea Biondi, EsPhALL Network/ BFM Study Group
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования
- Заболевания иммунной системы
- Инфекции
- Вирусные заболевания
- Новообразования по гистологическому типу
- Гематологические заболевания
- ДНК-вирусные инфекции
- Лимфатические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Лимфома, неходжкинская
- Лимфома, В-клеточная
- Лимфома
- Лейкемия, лимфоидная
- Лейкемия
- Вирусные инфекции Эпштейна-Барра
- Герпесвирусные инфекции
- Опухолевые вирусные инфекции
- Гемики и лимфатические заболевания
- Клетки-предшественники лимфобластный лейкоз-лимфома
- Лимфома Беркитта
- Т-клеточный лимфобластный лейкоз-лимфома-предшественник
- Лейкемия, бифенотипическая, острая
- Гормоны
- Гормоны, заменители гормонов и антагонисты гормонов
- Пептиды
- Аминокислоты, пептиды и белки
- Белки
- Средние соединения
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Терапия
- Хирургические процедуры, оперативные
- Нуклеиновые кислоты, нуклеотиды и нуклеозиды
- Углеводороды
- Углеводороды, циклические
- Биологические факторы
- Углеводы
- Карбоновые кислоты
- Алкалоиды
- Подофиллотоксин
- Тетрагидронафталины
- Нафталины
- Полициклические ароматические углеводороды
- Углеводороды, ароматные
- Полициклические соединения
- Глюкозиды
- Гликозиды
- Трансплантация
- Амиды
- Гидролазы
- Ферменты
- Ферменты и коэнзименты
- Индолы
- Пурины
- Цитидин
- Пиримидиновые нуклеозиды
- Пиримидины
- Беременные
- Беременные
- Стероиды
- Соединения слитого кольца
- Стероиды, фторированные
- Бензольные производные
- Сульфоновые кислоты
- Серные кислоты
- Фосфорамид горчицы
- Азотные соединения горчицы
- Горчичные соединения
- Углеводороды, галогенированные
- Фосфорамиды
- Соединения органофосфора
- Нуклеозиды
- Формилтетрагидрофолаты
- Тетрагидрофолаты
- Фолиевая кислота
- Птерины
- Птеридины
- Межклеточные сигнальные пептиды и белки
- Bergyadienetriols
- Амидогидролазы
- VINCA ALKALOIDS
- Секологические триптаминовые алкалоиды
- Индольные алкалоиды
- Индолизидины
- Индолизины
- Арабинонуклеозиды
- Аминоптерин
- Антрациклины
- Нафтацены
- Аминогликозиды
- Коэнзименты
- Гликопротеины
- Гликоконъюгаты
- Беременные
- БЕСПЛАТНЫЕ
- Трансплантация клеток
- Терапия на основе клеток и тканей
- Биологическая терапия
- 11-гидроксикортикостероиды
- Гидроксикортикостероиды
- Надпочечники коры гормонов
- 17-гидроксикортикостероиды
- Оксазины
- Кислоты, карбоциклический
- Бензолсульфонаты
- Арилсульфонаты
- Арилсульфоновые кислоты
- Бензоаты
- Колония стимулирующие факторы
- Факторы роста гематопоэтических клеток
- Цитокины
- Бензамиды
- Пиперазины
- Сульфгидрильные соединения
- Дикетопиперазины
- Иматиниб мезилат
- Дексаметазон
- Метотрексат
- Преднизолон
- Циклофосфамид
- Цитарабин
- Этопозид
- Лейковорин
- Леволейковорин
- Доксорубицин
- Винкристин
- Метилпреднизолон
- Даунорубицин
- Гидрокортизон
- Аспарагиназа
- Меркаптопурин
- Дексразоксан
- Разоксан
- Тиогуанин
- Ифосфамид
- Добезилат кальция
- Трансплантация стволовых клеток
- Дексаметазон 21-фосфат
- Гранулоцитарные колони-стимулирующие фактор
- Filgrastim
- Каласпаргаз Пегол
- азатиопурин
- Мерфос
- Pegaspargase
- ушной
- Дексаметазон ацетат
- ESIFONE
- Медрол Veriderm
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- AALL1631
- U10CA180886 (Грант/контракт NIH США)
- 2017 (Грант/контракт NIH США)
- AALL1631 (Другой идентификатор: CTEP)
- NCI-2016-01588 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- 2017-000705-20
- 2024-515499-12-00
- AALL1631 (Другой идентификатор: Children's Oncology Group)
- 2017-000705-20 (Номер EudraCT)
- 2024-515499-12-00 (Ктис)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .